Konica Minolta Unloads Ambry Medical Unit for $600 Million.
Debevoise & Plimpton LLP is representing Konica Minolta in the sale of its subsidiary, Ambry Genetics, to Tempus AI (NASDAQ: TEM). Under the terms of the deal, Tempus will acquire Ambry for $375 million in cash and $225 million in Tempus shares at closing, with $100 million of the shares subject to a one-year lock-up period.
For additional details, please refer to the company’s press release.
Ambry Genetics is a leading provider of genetic testing services, while Tempus AI is a technology-driven company focused on advancing precision medicine through the application of artificial intelligence in healthcare.
